Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) (NCT05943535)
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
🩺 Plain-English Summary (8th-Grade Level)
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Who can join: Review the eligibility criteria below.
Location: UAB Lung Health Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (165 Sites)
Showing the first 25 of 165 sites.
- UAB Lung Health Center — Birmingham, Alabama
- Banner University Medical Center Phoenix Lung Institute — Phoenix, Arizona
- Norton Thoracic Institute — Phoenix, Arizona
- Peter Morton Medical Building — Los Angeles, California
- NewportNativeMD, Inc. — Newport Beach, California
- University of California Irvine Medical Center — Orange, California
- Paradigm Clinical Research — Redding, California
- UC Davis Health Medical Center — Sacramento, California
- Paradigm Clinical Research — San Diego, California
- Stanford University Medical Center — Stanford, California
- Georgetown University Hospital — Washington D.C., District of Columbia
- Ascension Medical Group St. Vincent's Lung Institute — Jacksonville, Florida
- Mayo Clinic — Jacksonville, Florida
- TGH/USF Center for Advanced Lung Disease and Lung Transplant — Tampa, Florida
- Cleveland Clinic Florida — Weston, Florida
- The Emory Clinic — Atlanta, Georgia
- Northwestern Memorial Hospital, Clinical Research Unit — Chicago, Illinois
- Rush University Medical Center Outpatient Pulmonary Clinic — Chicago, Illinois
- UI Health Hospital — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- University of Kentucky — Lexington, Kentucky
- University of Louisville Healthcare Outpatient Research Clinic — Louisville, Kentucky
- Tulane Medical Center — New Orleans, Louisiana
- Johns Hopkins Asthma and Allergy Center — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (919) 485-8350
Email: clinicaltrials@unither.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Progressive Pulmonary Fibrosis
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis — Birmingham, Alabama
- PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis — Aurora, Colorado
- SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers — Charleston, South Carolina
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) — Birmingham, Alabama
Explore by condition: All Progressive Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.